South Korean pharmaceutical and chemical company Yuhan (KRX:000100) won a supply contract for AIDS treatment raw pharmaceutical ingredients (API) from California-based Gilead Sciences, according to a filing with the Korea Exchange on Wednesday.
The supply contract, valued at 84.3 billion won, represents 4.08% of Yuhan's latest annual sales.
Shares of Yuhan fell nearly 1% in recent trade.